Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
- Doctors develop possible cure for ‘bubble boy’ disease using gene therapy on April 18, 2019 at 3:16 am
(CNN) - In a major breakthrough for the medical world, doctors believe they have found a solution for children born with an immunodeficiency disorder known as “bubble boy" disease because of the 1976 ... […]
- Gene therapy could be a cure for 'bubble boy' disease on April 17, 2019 at 11:11 pm
They were once imprisoned in plastic bubbles that cut them off from the dangerous, infectious world. But now, children born with a disease that robs them of a functioning immune system may have gained ... […]
- Babies with 'bubble boy disease' cured using gene therapy developed by St. Jude's on April 17, 2019 at 5:53 pm
They were born without a working germ-fighting system, every infection a threat to their lives. Now 10 babies with "bubble boy disease" have had it fixed by a gene therapy made from one of the immune ... […]
- Study: Researchers successfully treat babies with 'bubble boy' disease using gene therapy on April 17, 2019 at 5:02 pm
MEMPHIS, Tenn. – Researchers from St. Jude Children’s Research Hospital have cured babies with “bubble boy” disease through gene therapy involving a re-engineered virus, according to a newly published ... […]
- New form of gene therapy could be a cure for ‘bubble boy’ disease on April 17, 2019 at 4:00 pm
An experimental treatment from St. Jude’s is being lauded by doctors as a cure for a condition often called “bubble boy” disease, because patients must stay inside and away from other people. The new ... […]
- Gene Therapy Restores Immunity for ‘Bubble Boys’ on April 17, 2019 at 3:48 pm
April 17, 2019 -- In 1971, a boy was born in Texas with a rare genetic defect that robbed him of an immune system. With the help of NASA engineers, David Vetter lived for years inside a series of ... […]
- Infants cured of 'bubble boy' immune disease with experimental gene therapy on April 17, 2019 at 3:15 pm
“Cure” is an elusive word, but it’s exactly what researchers at St. Jude Children’s Research Hospital are calling their treatment for the most common form of severe combined ... […]
- Gene therapy cures infants with ‘bubble boy’ immune disease on April 17, 2019 at 3:00 pm
Ten newborns with the rare genetic disorder known as bubble boy disease were cured with gene therapy, researchers revealed Wednesday. The treatment appears to have completely rid the babies of their ... […]
- Experimental gene therapy frees ‘bubble-boy’ babies from a life of isolation on April 17, 2019 at 2:38 pm
An experimental gene therapy has restored functioning immune systems to seven young children with a severe disorder that would have sentenced them to a life of isolation to avoid potentially deadly ... […]
- Doctors use HIV in gene therapy to fix 'bubble boy' disease on April 17, 2019 at 2:25 pm
They were born without a working germ-fighting system, every infection a threat to their lives. Now eight babies with "bubble boy disease" have had it fixed by a gene therapy made from one of the ... […]
via Google News and Bing News